Predictive value of adipokines for the severity of acute pancreatitis: a meta-analysis

• Published in: BMC gastroenterology Vol. 24; no. 1; p. 32
• Main Authors: Yu, Xuehua, Zhang, Ning, Wu, Jing, Zhao, Yunhong, Liu, Chengjiang, Liu, Gaifang
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 13.01.2024; BioMed Central; BMC
• Subjects: Acute pancreatitis; Adipocytes; Adipokines; Adiponectin; Adipose tissues; Analysis; Biological markers; Body fat; Care and treatment; Complications and side effects; Cytokines; Development and progression; Health aspects; Inflammation; Leptin; Meta-analysis; Obesity; Pancreatitis; Resistin; Sensitivity analysis; Serum levels; Therapeutic targets; Tumor necrosis factor-TNF; China; Acute pancreatitis; Adipokines; Meta-analysis; Resistin
• ISSN: 1471-230X; 1471-230X
• DOI: 10.1186/s12876-024-03126-w

Severe acute pancreatitis (SAP) is a dangerous condition with a high mortality rate. Many studies have found an association between adipokines and the development of SAP, but the results are controversial. Therefore, we performed a meta-analysis of the association of inflammatory adipokines with SAP. We screened PubMed, EMBASE, Web of Science and Cochrane Library for articles on adipokines and SAP published before July 20, 2023. The quality of the literature was assessed using QUADAS criteria. Standardized mean differences (SMD) with 95% confidence intervals (CI) were calculated to assess the combined effect. Subgroup analysis, sensitivity analysis and publication bias tests were also performed on the information obtained. Fifteen eligible studies included 1332 patients with acute pancreatitis (AP). Pooled analysis showed that patients with SAP had significantly higher serum levels of resistin (SMD = 0.78, 95% CI:0.37 to 1.19, z = 3.75, P = 0.000). The difference in leptin and adiponectin levels between SAP and mild acute pancreatitis (MAP) patients were not significant (SMD = 0.30, 95% CI: -0.08 to 0.68, z = 1.53, P = 0.127 and SMD = 0.11, 95% CI: -0.17 to 0.40, z = 0.80, P = 0.425, respectively). In patients with SAP, visfatin levels were not significantly different from that in patients with MAP (SMD = 1.20, 95% CI: -0.48 to 2.88, z = 1.40, P = 0.162). Elevated levels of resistin are associated with the development of SAP. Resistin may serve as biomarker for SAP and has promise as therapeutic target.